| Stages of GOLD 2010 | SABD | LABD | IC | Methylxanthines | Mucolytic agents | IF-4 | |
| At diagnosis | I | 58% | 71% | 22% | 0 | 16% | 0 |
| II | 69% | 64% | 44% | 5% | 26% | 0 | |
| III | 77% | 70% | 55% | 19% | 37% | 3% | |
| IV | 77% | 65% | 54% | 27% | 35% | 0 | |
| Unknown | 39% | 38% | 26% | 5% | 16% | 1% | |
| At present | I | 33% | 96% | 37% | 0 | 37% | 1% |
| II | 44% | 93% | 52% | 6% | 26% | 9% | |
| III | 58% | 95% | 75% | 10% | 34% | 18% | |
| IV | 64% | 96% | 89% | 21% | 39% | 29% | |
| Unknown | 40% | 84% | 49% | 5% | 27% | 9% |
SABD: Short-acting bronchodilators; LABD: Long-acting bronchodilators, CI: Inhaled glucocorticoids; IF-4: inhibitor of the enzyme PDE-4